Literature DB >> 2015700

Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states.

E N Sarno1, G E Grau, L M Vieira, J A Nery.   

Abstract

The possible role of cytokines in leprosy reactions was investigated by analysing the levels of tumour necrosis factor (TNF) and interleukin-1 (IL-1) in serum samples from 39 leprosy patients, 22 of them presenting either type I (upgrading) or type II (ENL) reactions. Fifty per cent of the patients showed elevated concentrations of TNF and IL-1 in at least one of the serum samples tested. This included all four patients undergoing type I reversal reaction and nine (50%) of the ENL patients studied. Concentrations of TNF above 1000 pg/ml were found in four patients with ENL. Development of erythema multiforme in these ENL patients represented an aggravating factor and all four patients suffering from this type of lesion demonstrated increased serum TNF levels. All BT patients tested presented elevated IL-1 levels, while only half of them presented elevated levels of TNF. No correlation was found between any particular systemic symptoms and the levels of TNF and IL-1. These results suggest that TNF and IL-1 may be implicated in leprosy reactions, either acting directly or in synergism with other cytokines.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2015700      PMCID: PMC1535359     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  34 in total

1.  Erythema nodosum leprosum.

Authors:  M Vázquez-Botet; J L Sánchez
Journal:  Int J Dermatol       Date:  1987-09       Impact factor: 2.736

Review 2.  Cytokines as inflammatory mediators.

Authors:  M E Billingham
Journal:  Br Med Bull       Date:  1987-04       Impact factor: 4.291

Review 3.  Reactions in leprosy. Clinical aspects.

Authors:  V N Sehgal
Journal:  Int J Dermatol       Date:  1987-06       Impact factor: 2.736

4.  Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy.

Authors:  T D Rao; P R Rao
Journal:  Int J Lepr Other Mycobact Dis       Date:  1987-03

5.  Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria.

Authors:  G E Grau; L F Fajardo; P F Piguet; B Allet; P H Lambert; P Vassalli
Journal:  Science       Date:  1987-09-04       Impact factor: 47.728

6.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura.

Authors:  E Girardin; G E Grau; J M Dayer; P Roux-Lombard; P H Lambert
Journal:  N Engl J Med       Date:  1988-08-18       Impact factor: 91.245

7.  Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function.

Authors:  D K Blanchard; J Y Djeu; T W Klein; H Friedman; W E Stewart
Journal:  J Leukoc Biol       Date:  1988-05       Impact factor: 4.962

Review 8.  The role of tumor necrosis factor (cachectin) in cachexia.

Authors:  A Oliff
Journal:  Cell       Date:  1988-07-15       Impact factor: 41.582

9.  Type 1 reactions in leprosy--heterogeneity in T-cell functions related to the background leprosy type.

Authors:  S Laal; R S Mishra; I Nath
Journal:  Int J Lepr Other Mycobact Dis       Date:  1987-09

10.  Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.

Authors:  P F Piguet; G E Grau; B Allet; P Vassalli
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

View more
  53 in total

1.  Inhibition of apoptosis by ionomycin and zinc in peripheral blood mononuclear cells (PBMC) of leprosy patients.

Authors:  A Gupta; V K Sharma; H Vohra; N K Ganguly
Journal:  Clin Exp Immunol       Date:  1999-07       Impact factor: 4.330

2.  Reactions following completion of 1 and 2 year multidrug therapy (MDT).

Authors:  Ma Victoria F Balagon; Robert H Gelber; Rodolfo M Abalos; Roland V Cellona
Journal:  Am J Trop Med Hyg       Date:  2010-09       Impact factor: 2.345

3.  Soluble tumor necrosis factor alpha receptors in sera from leprosy patients.

Authors:  M E Munk; P Anding; A P Schettini; M G Cunha; S H Kaufmann
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 4.  Mycobacterium leprae-host-cell interactions and genetic determinants in leprosy: an overview.

Authors:  Roberta Olmo Pinheiro; Jorgenilce de Souza Salles; Euzenir Nunes Sarno; Elizabeth Pereira Sampaio
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

5.  IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells.

Authors:  S M Thakurdas; Z Hasan; R Hussain
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

6.  Interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) are necessary in the early stages of induction of CD4 and CD8 cytotoxic T cells by Mycobacterium leprae heat shock protein (hsp) 65 kD.

Authors:  M C Sasiain; S de la Barrera; S Fink; M Finiasz; M Alemán; M H Fariña; G Pizzariello; R Valdez
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

7.  Tumor necrosis factor production in patients with leprosy.

Authors:  P F Barnes; D Chatterjee; P J Brennan; T H Rea; R L Modlin
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

8.  Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence.

Authors:  L B Adams; Y Fukutomi; J L Krahenbuhl
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  Predicting neuropathy and reactions in leprosy at diagnosis and before incident events-results from the INFIR cohort study.

Authors:  W Cairns S Smith; Peter G Nicholls; Loretta Das; Pramila Barkataki; Sujai Suneetha; Lavanya Suneetha; Rupendra Jadhav; P S S Sundar Rao; Einar P Wilder-Smith; Diana N J Lockwood; Wim H van Brakel
Journal:  PLoS Negl Trop Dis       Date:  2009-08-11

10.  Inhibition of tumor necrosis factor-alpha by thalidomide in magnesium deficiency.

Authors:  W B Weglicki; R E Stafford; B F Dickens; I T Mak; M M Cassidy; T M Phillips
Journal:  Mol Cell Biochem       Date:  1993-12-22       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.